Pulmonary homing of mesenchymal stem cells: From embolism risk to a therapeutic advantage in pneumonia (Review)

Mesenchymal stem cells (MSCs) hold notable therapeutic potential for pneumonia, yet their intravenous administration is limited by pulmonary homing, in which the majority of infused cells become trapped in the lung microvasculature due to their size. Historically considered an embolic hazard and a barrier to systemic delivery, this phenomenon may instead be advantageous when the lung is the intended therapeutic target. The present review reframes pulmonary homing as a potential therapeutic delivery advantage for pneumonia treatment and summarizes the updated consensus criteria for defining MSCs and compares the key features of mesodermal‑ vs. ectodermal‑derived MSC populations. How MSCs temper pneumonia‑associated cytokine storms by modulating macrophage pyroptosis, neutrophil extracellular trap formation and natural killer cell activity is also examined. Finally, the mechanisms that drive pulmonary entrapment are reviewed and the balance between therapeutic benefit and embolic risk is considered. Reinterpreting a long‑perceived liability as a therapeutic asset relies on a detailed understanding of the biophysical and molecular determinants that govern MSC retention in the lung.

Authors

Institutions

Publication Details

Journal
Experimental and Therapeutic Medicine
Published
2026-11-18
DOI
https://doi.org/10.3892/etm.2026.13360
Primary Topic
Mesenchymal stem cell research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Pulmonary homing of mesenchymal stem cells: From embolism risk to a therapeutic advantage in pneumonia (Review)

Riting Zhang, Denghua Ren, Tongtong Xie, Min Li et al.
Experimental and Therapeutic Medicine
Mesenchymal stem cell research
article

Pulmonary homing of mesenchymal stem cells: From embolism risk to a therapeutic advantage in pneumonia (Review)

Riting Zhang, Denghua Ren, Tongtong Xie, Min Li, Hao Lü, Ming Yin, Xingxing Suo, Wentao Shi
article en

Abstract

Mesenchymal stem cells (MSCs) hold notable therapeutic potential for pneumonia, yet their intravenous administration is limited by pulmonary homing, in which the majority of infused cells become trapped in the lung microvasculature due to their size. Historically considered an embolic hazard and a barrier to systemic delivery, this phenomenon may instead be advantageous when the lung is the intended therapeutic target. The present review reframes pulmonary homing as a potential therapeutic delivery advantage for pneumonia treatment and summarizes the updated consensus criteria for defining MSCs and compares the key features of mesodermal‑ vs. ectodermal‑derived MSC populations. How MSCs temper pneumonia‑associated cytokine storms by modulating macrophage pyroptosis, neutrophil extracellular trap formation and natural killer cell activity is also examined. Finally, the mechanisms that drive pulmonary entrapment are reviewed and the balance between therapeutic benefit and embolic risk is considered. Reinterpreting a long‑perceived liability as a therapeutic asset relies on a detailed understanding of the biophysical and molecular determinants that govern MSC retention in the lung.

Experimental and Therapeutic MedicineVol. 33(1)
Jiangnan University (CN), Soochow University (CN), Zhongda Hospital Southeast University (CN), Wuxi No.2 People's Hospital (CN), Wuxi Ninth People's Hospital (CN), Wuxi People's Hospital (CN)
National Natural Science Foundation of China
Good health and well-being
Mesenchymal stem cell research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon